Intervention not reported
Adverse events ‐ Withdrawn for medical reasons: SSRI versus placebo · patients with depression during opioid agonist treatment for opioid dependence
The intervention showed no clear difference in adverse events ‐ Withdrawn for medical reasons: SSRI versus placebo (high certainty).
1 finding from 1 review
Adverse events (total adverse events) (oestrogen cream vs non‐hormonal lubricant gel) · postmenopausal women with vaginal atrophy
Oestrogen tablets showed no clear difference in adverse events (total adverse events) (oestrogen tablets vs placebo) compared with other regimens (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Withdrawn for medical reasons: Tricyclics versus placebo · patients with depression during opioid agonist treatment for opioid dependence
The intervention leads to higher adverse events ‐ Withdrawn for medical reasons: Tricyclics versus… (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events for all placebos compared with wait‐list or no treatment (Spontaneous reporting of dichotomous outcomes) (Post‐treatment) · patients with mental health disorders
It is very uncertain whether the intervention changes serious adverse events for all placebos compared with wait‐list or… (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious adverse events for all placebos compared with wait‐list or no treatment (Spontaneous reporting of dichotomous outcomes) (Post‐treatment) · patients with mental health disorders
It is very uncertain whether the intervention changes non‐serious adverse events for all placebos compared with wait‐list… (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events 4 studies reported the frequency of self reported adverse events in the AED and placebo groups The results show a trend in favour of the placebo groups · people with epilepsy and intellectual disability
The intervention showed no clear difference in adverse events 4 studies reported the frequency of self reported… (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events 1. All adverse events 2. Drop‐outs due to adverse events 3. Severe hypoglycaemia a. Intervention vs placebo [1a. 24 weeks] [2a. 24 weeks to 56 weeks] b. Intervention vs metformin [1b. 6 months to 4 years] [2b. 24 weeks to 4 years] [... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in adverse events 1. All adverse events 2. Drop‐outs due to adverse… (low certainty).
1 finding from 1 review
RR 0.91 [0.51, 1.62]
1 study · 2 participants
Low
Adverse events · carpal tunnel syndrome
1 finding from 1 review
Adverse events · postmenopausal women with osteoporosis and CKD stages 5 and 5D
1 finding from 1 review
Adverse events · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · adults with GA due to AMD
1 finding from 1 review
Adverse events · adults with GA due to AMD
1 finding from 1 review
Adverse events · Adults with COPD
1 finding from 1 review
Adverse events · Preschool children (<6 years)
Intermittent ICS showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · School‐aged children and adults
Intermittent ICS showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events (any) · people with asthma
Anti‐IL13 or anti‐IL4 agents leads to higher adverse events (any) compared with placebo (high certainty).
1 finding from 1 review
Total adverse events · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with asthma
Anti‐IL13 or anti‐IL4 agents showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with hepatic encephalopathy
1 finding from 1 review